SEC Form 10-K filed by Anebulo Pharmaceuticals Inc.
$ANEB
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three and twelve months ended June 30, 2025, and recent updates. Fourth Quarter Fiscal Year 2025 and Subsequent Highlights: On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will investigate the safety,
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announces the first subjects dosed in its Phase 1 single ascending dose ("SAD") study of intravenous (IV) selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA). First Subjects Dosed in Phase 1 SAD Study of Intravenous Selonabant Second year of NIDA collaborative grant ($994,300) awarded "This important milestone brings Anebulo closer to its goal of providing the first emergency antidote for ac
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announces an update on its current going private transaction. After announcing a going private transaction on July 23, 2025, the Company received inbound interest from potential financial and strategic partners. Consistent with our commitment to maximize stockholder value, the Board will review all strategic alternatives available to the Company, including the proposed going private transaction and related reverse stock split, a sale of the Company's assets and/or a merger trans
4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)
4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)
4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)
10-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
S-8 POS - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio
Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction, today announced the appointment of Sandra Gardiner as the Company's acting chief financial officer. Ms. Gardiner joins Anebul
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board. "We are very pleased to welcome Nat to the Anebulo Board," said Simon Allen, Chief Executive Officer of Anebulo. "Nat's deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001." Dr. Calloway is an analys
Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact
2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst
Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the "Company" or "Anebulo"), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of